Transforming lives through next-generation immunotherapies
Developing a first-in-class AutoRegulation technology to create safer and more efficient drugs
About us
NovalGen is a clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders
Our technologies
We are changing the paradigm of immunotherapies with our AutoRegulation platform technology. This groundbreaking approach integrates self-regulating capabilities into a range of immunotherapies tailored to improve clinical outcomes in patients.
Pipeline
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.
